title: The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment.
abstract: OBJECTIVE
  Anticholinergic medication is the mainstay of pharmacotherapy for overactive bladder (OAB). The aim of the study is to investigate the effect of oral solifenacin succinate on intraocular pressure (IOP) in female OAB patients and to discuss the ocular drawbacks during treatment.
  
  
  METHODS
  The female patients with a clinical diagnosis of OAB in whom use of oral solifenacin succinate 5 mg/day (group I) and age-matched healthy female subjects (group II) underwent complete ophthalmological examination, including IOP measurement at the beginning of the oral treatment and after 4 weeks. The patients with a history of previous ocular surgery and those with ocular diseases besides refraction disorders and presbyopia were excluded.
  
  
  RESULTS
  The data from the right eyes of 60 consecutive patients in group I and 30 consecutive patients in group II were used for analysis. No statistically significant change was detected in the IOP (from 16.05 ± 2.30 mmHg to 16.30 ± 2.25 mmHg at the 4th week in group I, p = 0.160; from 15.60 ± 2.14 mmHg to 15.60 ± 2.09 mmHg at the 4th week in group II, p = 0.864) of the eyes in both groups.
  
  
  CONCLUSIONS
  Since the power of the study is not enough to draw a clear conclusion, a 4-week course of solifenacin succinate treatment in women with OAB seemed to have no clinically significant effect on IOP values. Further larger studies are needed to determine the effect of anticholinergics on anterior chamber parameters and to evaluate their safety in glaucoma patients.
authors.affiliation: Ulucanlar Eye Training and Research Hospital, Ophthalmology Department, Ankara, Turkey, msekeroglu@yahoo.com.
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Sekeroglu
authors.forename: Emre
authors.initials: E
authors.lastname: Hekimoglu
authors.forename: Ikbal Seza
authors.initials: IS
authors.lastname: Petricli
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Tasci
authors.forename: Ismail
authors.initials: I
authors.lastname: Dolen
authors.forename: Umut
authors.initials: U
authors.lastname: Arslan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005901:Glaucoma / Q000139:chemically induced; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D011812:Quinuclidines / Q000494:pharmacology* / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate